ZURICH - The Swiss pharmaceutical group Roche Holding AG has risen much faster than the market in years, the group's leader was quoted as saying in an interview with the Swiss newspaper Sonntagszeitung.
"2009 will be a very good year. Even without Tamiflu, we will significantly overtake the market. Thanks to the quality of our portfolio we are also able to strengthen our market position in the long term," said CEO Severin Schwan.
Roche has 10 new officers to look for late stage development, Schwan said.
Roche, the first global manufacturer of medicines for cancer, posted a forecast beating up 10 percent of sales in the third quarter in October, helped by demand for Tamiflu, an antiviral drug due to a pandemic of H1N1 swine flu.
GM Hot News
